Related Experiment Video

Updated: Aug 14, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Current status of small-molecule tyrosine kinase inhibitors targeting epidermal growth factor receptor in colorectal

Timothy Kuo1, George A Fisher

  • 1Division of Medical Oncology, Stanford Cancer Center, 875 Blake Wilbur Drive, Stanford, CA 94305, USA.

Clinical Colorectal Cancer
|December 13, 2005
PubMed

Insights

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) show promise in colorectal cancer (CRC) when combined with chemotherapy, suggesting synergistic effects. Further research into newer TKIs targeting multiple pathways is ongoing for CRC treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacogenomics

Background:

  • Epidermal growth factor receptor (EGFR) is highly expressed in colorectal cancers (CRCs), correlating with poor prognosis.
  • Monoclonal antibodies targeting EGFR demonstrate antitumor activity in CRC.
  • Small-molecule tyrosine kinase inhibitors (TKIs) offer advantages over antibodies but have shown limited single-agent efficacy in CRC.

Purpose of the Study:

  • To investigate the potential synergistic effect of EGFR TKIs combined with chemotherapy in metastatic colorectal cancer.
  • To explore the reasons for differential responses to EGFR TKIs between colorectal cancer and non-small-cell lung cancer.
  • To highlight emerging strategies involving next-generation TKIs targeting multiple receptor pathways in CRC.

Main Methods:

  • Review of early-phase clinical trials of EGFR TKIs in colorectal cancer.
  • Comparison of EGFR expression and mutation status in colorectal cancer versus non-small-cell lung cancer.
  • Discussion of ongoing research into novel multi-targeted TKIs for colorectal cancer.

Main Results:

  • Gefitinib (an EGFR TKI) combined with chemotherapy showed unusually high response rates in metastatic CRC.
  • This synergistic effect was not observed in non-small-cell lung cancer (NSCLC).
  • Differences in EGFR status between CRC and NSCLC do not fully explain the observed dichotomy.

Conclusions:

  • Combination therapy with EGFR TKIs and chemotherapy may offer a synergistic benefit in colorectal cancer.
  • Further pharmacogenomic investigation is needed to understand EGFR tyrosine kinase inhibition in CRC.
  • Newer generations of multi-targeted TKIs are under investigation for colorectal cancer treatment.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...